Abstract
Anti-tumor necrosis factor-α therapy has been paradoxically associated with the new development or worsening of existing psoriasis. We describe the case of a patient who experienced a flare of pustular psoriasis after initiating anti-interleukin-12/23 therapy, which subsequently improved following discontinuation of the drug.
Key words::
Acknowledgement
Funding: Dr Wenk is a research fellow whose fellowship is partially supported by Abbott and Centocor Ortho Biotech Inc.
Declaration of interest: Dr Ehrlich has served as a principal investigator on research studies supported by Abbott, Amgen, Genentech and Centocor Ortho Biotech Inc. She is on the speakers' bureau for Abbott.